SCHEMBL20118005

SCHEMBL20118005

CC(=O)SCCNC(=O)CCN

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
RAB9A P51151 1/20 0.38
TSHR P16473 3/20 0.38
CYP2C19 P33261 2/20 0.37
HDAC3 O15379 2/20 0.37
HDAC4 P56524 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC7 Q8WUI4 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC10 Q969S8 2/20 0.37
HDAC11 Q96DB2 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC9 Q9UKV0 2/20 0.37
HDAC5 Q9UQL6 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
ALDH1A1 P00352 4/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10490875 0.89 SLC6A5 (0.42) TSHRHDAC3HDAC4HDAC1HDAC7
SCHEMBL10490814 0.84 CYP2C19 (0.43) KMT2AMEN1RAB9ATSHRCYP2C19
SCHEMBL6236684 0.82 CASP2 (0.52) TSHRCYP2C19HDAC3HDAC1HDAC2
SCHEMBL18714373 0.81 PHF8 (0.45) KMT2AMEN1RAB9ATSHRHDAC3
SCHEMBL10954634 0.81 TSHR (0.52) KMT2AMEN1RAB9ATSHRCYP2C19
SCHEMBL3548845 0.80 ALDH1A1 (0.54) KMT2AMEN1RAB9ATSHRCYP2C19
Alethine SCHEMBL689905 0.79 TSHR (0.41) KMT2AMEN1RAB9ATSHRCYP2C19
SCHEMBL15131923 0.79 PAOX (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6240142 0.78 CYP2C19 (0.38) KMT2AMEN1RAB9ATSHRCYP2C19
SCHEMBL14959901 0.78 TEAD1 (0.49) KMT2AMEN1TSHRCYP2C19HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118767-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS COMET THERAPEUTICS B.V. (NL) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118767-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS PANK3, PANK1, PANK2 KMT2A 1462/4885MEN1 1020/4885RAB9A 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.